Download PDF
Synthesis 2005(9): 1550-1554  
DOI: 10.1055/s-2005-865324
PAPER
© Georg Thieme Verlag Stuttgart · New York

Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors Based on a Tetrahydro-1(2H)-isoquinolinone Scaffold: Synthesis, Biological Evaluation and X-ray Crystal Structure

Stefan Peukert*, Uwe Schwahn, Stefan Güssregen, Herman Schreuder, Armin Hofmeister
Aventis Pharma Deutschland GmbH, a company of the sanofi-aventis group, TD Cardiovascular, TD Thrombosis and Angiogenesis and Chemical Sciences, 65926 Frankfurt, Germany
Fax: +49(69)331399; e-Mail: armin.hofmeister@sanofi-aventis.com;
Further Information

Publication History

Received 23 December 2004
Publication Date:
19 April 2005 (online)

    Permissions and Reprints All articles of this category

Abstract

The synthesis, activity and physical properties of two series of novel potent tetrahydro-1(2H)-isoquinolinone based PARP-1 inhibitors are described. The new structural classes with a non-planar ring system interact specifically with the PARP-1 protein at the nicotinamide-binding site.

Key words

medicinal chemistry - PARP inhibitors - structure-activity relationship - isoquinolinones - crystal structure

    References

  • 2 Review: Smith S. Trends Biochem. Sci.  2001,  26:  174 
    CrossrefGoogle Scholar
  • 3 Review: Virag L. Szabo C. Pharmacol. Rev.  2002,  45:  73 
    Google Scholar
  • 4 Eliasson MJL. Sampei K. Mandir AS. Hurn PD. Traystman RJ. Bao J. Pieper A. Wang Z.-Q. Dawson TM. Snyder SH. Dawson VL. Nat. Med.  1997,  3:  1089 
    CrossrefGoogle Scholar
  • 5a Komjati K. Mabley JG. Virag L. Southan GJ. Salzman AL. Szabo C. Int. J. Mol. Med.  2004,  273:  373 
    CrossrefGoogle Scholar
  • 5b Ferraris D. Ko YS. Pahutski T. J. Med. Chem.  2003,  46:  3138 
    CrossrefGoogle Scholar
  • 5c Calabrese CR. Almassy R. Barton S. Batey MA. Calvert AH. Canan-Koch S. Durkacz BM. Hostomsky Z. Kumpf RA. Kyle S. Li J. Maegley K. Newell DR. Notarianni E. Stratford IJ. Skalitzky D. Thomas HD. Wang L.-Z. Webber SE. Williams KJ. Curtin NJ. J. Natl. Cancer Inst.  2004,  96:  56 
    CrossrefGoogle Scholar
  • 6 Ruf A. De Murcia G. Schulz GE. Biochemistry  1998,  37:  3893 
    CrossrefGoogle Scholar
  • 7 Banasik M. Komura H. Shimoyama M. Ueda K. J. Biol. Chem.  1992,  267:  1569 
    Google Scholar
  • 8 Li J.-H, Tays KL, and Zhang L. inventors; Guildford Pharmaceuticals  WO 9911624.  ; Chem. Abstr. 1999, 130, 218328
  • 9 Peukert S. Schwahn U. Exp. Opin. Ther. Pat.  2004,  14:  1531 
    CrossrefGoogle Scholar
  • 10 Falk H. Suste A. Monatsh. Chem.  1994,  125:  325 
    CrossrefGoogle Scholar
  • 11 Netherton MR. Fu GC. Org. Lett.  2001,  3:  4295 
    CrossrefPubMedGoogle Scholar
  • 12 Meudt A. inventors; Clariant GmbH, WO  03033503.  ; Chem. Abstr. 2003, 138, 321392
  • 13 The catalytic fragment of chicken PARP-1 was obtained from Prof. DeMurcia of the Ecole Supérieure de Biotechnology de Strasbourg. Native PARP-1 was crystallized at pH 8.5 with 18% PEG 4000 and 8% i-PrOH as precipitant, following the protocol of Jung et al.: Jung S. Miranda EA. De Murcia JM. Niedergang C. Delarue M. Schulz GE. DeMurcia GM. J. Mol. Biol.  1994,  244:  114 . Inhibitor complexes were obtained by soaking native crystals with the appropriate inhibitors. The space group and cell dimensions of the crystals obtained were the same as in the published crystal structures. We obtained well diffracting crystals, diffracting to 2.2 and 2.1 Å resolutions, respectively. We did not observe any major differences between our PARP structures and the PARP structures present in the PDB
    CrossrefGoogle Scholar
  • 14 Ruf A. De Murcia JM. De Murcia GM. Schulz GE. Proc. Natl. Acad. Sci. U.S.A.  1996,  93:  7481 
    CrossrefGoogle Scholar
1

New address: S. Peukert, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA; E-Mail: stefan.peukert@novartis.com.